Table of Contents:
  • Contents: Routine use of genetic evidence in drug target discovery and validation
  • Genetically supported targets can double the success rate in clinical development
  • COPD has the highest prevalence of chronic respiratory diseases globally
  • SpiroMeta consortium: understanding the genetic determinants of COPD
  • Understanding the tractability of drug targets
  • Identification of statistically independent genetic associations (signals) for lung function
  • Use of phonome-wide association studies
  • DeepPheWAS: testing pathway-specific GRS to infer possible consequences of intervening in pathways underlying lung function